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SUMMARY 23 
Thyroglobulin is the protein precursor of thyroid hormones, which are essential for 24 
growth, development and control of metabolism in vertebrates1,2. Hormone synthesis 25 
from thyroglobulin (TG) occurs in the thyroid gland via the iodination and coupling of 26 
pairs of tyrosines and is completed by TG proteolysis3. Tyrosine proximity within TG is 27 
thought to enable the coupling reaction but hormonogenic tyrosines have not been 28 
clearly identified and the lack of a three-dimensional structure of TG has prevented 29 
mechanistic understanding4. Here we present the structure of full-length human 30 
thyroglobulin at ~3.5 Å resolution determined by electron cryomicroscopy (cryo-EM). 31 
We identified all hormonogenic tyrosine pairs in the structure and verified them via 32 
site-directed mutagenesis and in vitro hormone production assays using human TG 33 
expressed in HEK cells. Analysis revealed that proximity, flexibility and solvent 34 
exposure of the tyrosines are the key characteristics of hormonogenic sites. 35 
Transferring the reaction sites from TG to an engineered tyrosine donor-acceptor pair 36 
in the unrelated bacterial maltose binding protein (MBP) yielded hormone production 37 
with efficiency comparable to TG. Our study provides a framework to further 38 
understand the production and regulation of thyroid hormones.  39 
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MAIN 40 
Tetraiodothyronine (thyroxine, T4) and triiodothyronine (T3) are iodine-containing 41 
thyroid hormones (TH) that regulate metabolism and many other fundamental 42 
processes in vertebrates1,5. T4 and smaller amounts of T3 are found in the bloodstream 43 
of healthy humans3, whereas suboptimal levels of TH have dramatic consequences for 44 
heart rate, brain function and foetal development. Approximately 5% of the world's 45 
human population suffer from thyroid diseases, but the molecular events behind TH 46 
synthesis are yet to be completely understood6. 47 
TH synthesis is stimulated by TSH (thyroid stimulating hormone), itself produced in 48 
pituitary gland, to occur in the thyroid from the protein precursor thyroglobulin (TG). 49 
Iodide (I-) is accumulated in the thyroid both in the cytoplasm and lumen of thyroid 50 
follicular cells (colloid), into which TG is secreted in high amounts2,7. Two apical 51 
membrane enzymes dual oxidases (DUOX, producing H2O2) and thyroid peroxidase 52 
(TPO, oxidising iodide) allow the extracellular iodination of tyrosine residues within the 53 
TG protein substrate3,8. TG, a protein dimer of 600 kDa, has an unusually high number 54 
of ~ 60 disulfide bonds per monomer and 17 glycosylation sites, which confer 55 
remarkable stability and solubility to the protein1,2,9. Of ~30 iodinated tyrosines in TG 56 
per monomer (out of 66), only a small number are hormonogenic, i.e. are a substrate for 57 
TH formation. In the hormonogenic sites, after iodination, the aromatic ring of a donor 58 
di- (or mono-) iodo-tyrosine is transferred to a proximal acceptor di-iodo-tyrosine, 59 
thereby forming T4 (or T3) hormone, still connected to the polypeptide backbone, while 60 
leaving a dehydroalanine at the donor position10. After endocytosis from the colloid to 61 
cytoplasmic lysosomes, TG is proteolysed in follicular cells and releases free TH 62 
(Extended Data Figure 1)11,3. Furthermore, a thyroid dehalogenase (Dehal1) recycles 63 
iodide stored in non-hormonogenic iodotyrosines of TG12. 64 
Mass spectrometry analyses of thyroid-extracted TG have identified four or more 65 
acceptor tyrosines, but the position of the donors has remained unclear13.  66 
We recombinantly produced full-length non-iodinated human TG in HEK293T cells 67 
(rTG)14. rTG appears to be indistinguishable by SDS-PAGE and cryo-EM from 68 
endogenous TG purified from thyroid glands of goitrous patients (eTG), which is partly 69 
iodinated (Extended Data Figure 2 a-c). In cryo-EM, TG has a bilobed shape with 70 
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average dimensions of 120 x 235 Å, which correlate well with previously reported 71 
negative staining EM data15. We collected cryo-EM datasets for both rTG and eTG and 72 
obtained very similar reconstructions at the resolution of ~3.5 Å (Extended Data Figure 73 
2 d-g, Extended Data Table 1). The initial maps obtained by imposing C2 symmetry 74 
showed local resolutions ranging from ~3 to ~6 Å. Symmetry expansion and focussed 75 
refinements improved the quality of the peripheral regions (Extended Data Figure 2 e). 76 
Using a combination of de novo and homology modelling we built a TG atomic model 77 
covering 93% of its 2749 amino acids, with variable local quality (Extended Data Figure 78 
3).  79 
TG's sequence is dominated by a number of cysteine rich domains, which have been 80 
named type 1, 2 and 3 thyroglobulin-like repeats (Figure 1a)16,17,18. TG-repeats are 81 
spaced by linker domains and connected to a C-terminal choline esterase-like domain 82 
(ChEL). Following the domain arrangement in the context of TG's 3D structure, we 83 
defined five TG regions: NTD (N-terminal domain), Core, Flap, Arm and CTD (C-terminal 84 
domain), as indicated in Figures 1a-b. TG's dimer interface is very large at 29,350 Å2 85 
(Figures 1c-e, Supplementary Video 1). In the TG monomer, the globular NTD is 86 
connected to the Core region via a linker (residues 610-620), crossing the central dimer 87 
interface and it is partially flexible (Extended Data Figure 2f). The Core contains two 88 
triplets of type-1 repeats (domain H with a very large insertion), separated by domain I, 89 
located near the C2 axis. The Core is then connected to the Flap region, which is 90 
composed of two Ig-like domains, M and N. The Flap extends along the minor axis of the 91 
molecule with the M domain protruding at the opposite side of the NTD and folding 92 
back onto the Arm region. The Arm consists of a rod-shaped arrangement formed by 93 
concatenated type-2 TG repeats with a laminin-like fold and by a single type-1 repeat P. 94 
This is followed by a series of type-3 TG repeats, tightly docking onto each other in an 95 
arc towards the direction of the C2 axis. The Arm is linked to the CTD region, 96 
corresponding to the dimeric ChEL domain, located near the C2 axis. Overall, TG's 97 
structure appears entangled and revolves around the central ChEL dimer that interacts 98 
with different regions of the Arm and the Core of the same chain and, via the E domain, 99 
with the NTD of the other chain. Due to the intertwined nature of the dimer, the NTD 100 
interacts with all regions of the other subunit of the dimer. To validate the complex TG 101 
architecture, we used crosslinking mass spectrometry and found that the predicted 102 
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inter- and intra-molecular links from our atomic model are in excellent agreement with 103 
experimental crosslinks (Extended Data Figure 4). For example, we detected long-range 104 
crosslinks that are consistent with the TG fold where the NTD crosses the ChEL dimer 105 
interface: 539-2524, the N-terminus with 178 and the Arm region 1987-1990 (Extended 106 
Data Figure 4d-f). Most of TG's disulfide bonds show clear EM density in our maps 107 
(Extended Data Figure 5a) and we found no inter-subunit disulfide bonds, in agreement 108 
with previous observations that TG is a non-covalent dimer19. We resolved 12 109 
previously predicted N-linked GlcNac in our maps, and four that had not been identified, 110 
at N110, N484, N1869 and N212220 (Extended Data Table 3). Some glycans are partially 111 
buried and are resistant to treatment with deglycosylases, as shown by EM. Notably, the 112 
glycans linked to N2013 mediate the contact between the NTD and CTD and might 113 
contribute to the dimer stability (Extended Data Figure 5b & f, Supplementary Video 1).  114 
We inspected our structure within a 15 Å radius of the reported acceptor tyrosines 115 
(designated Sites A-D)21 and identified putative donor tyrosines (Figure 2a). Acceptor 116 
Y24 (partially disordered) at Site A appears to have two possible donor partners Y234 117 
and Y149 (donor 1 and donor 2). In Site B the acceptor Y2573 pairs with donor Y2540; 118 
At Site C, Y2766, not resolved in our maps, probably acts both as donor and acceptor 119 
across the C2 dimer axis19. In Site D the acceptor Y1310 pairs with Y108 of the other 120 
subunit (Figure 2a). Therefore, TG likely contains four hormonogenic acceptor tyrosines 121 
and five donor tyrosines. We verified this by comparing the amount of TH obtained 122 
from unmodified rTG and rTG variants where acceptor or donor tyrosines were 123 
mutated to phenylalanines, abolishing hormone formation. TH synthesis was performed 124 
by rTG in vitro iodination, and the T4 or T3 concentrations were measured by adapting 125 
a commercial ELISA assay (Extended Data Figure 6)22,23. Using our reaction conditions, 126 
we could only detect significant production of T4, but not of T3 (Extended Data Figure 127 
6f-g). We used lactoperoxidase (LPO) in all other reactions, since it showed the same 128 
activity as TPO in our assay8. As shown in Figure 2c, when we mutated all acceptors 129 
(Y24, Y2573, Y2766 and Y1310)21,13 we observed no T4 synthesis, demonstrating that 130 
there are no more than four significant hormonogenic sites in TG. A residual activity, 131 
corresponding to about a third of unmodified rTG activity, was detected by mutating all 132 
but one of the proposed donors for Site A: those at Sites B, C and D (Y2540, Y2766 and 133 
Y108), and either donor 1 or donor 2 at Site A (Y234 and Y149). When all five proposed 134 
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donors were mutated, no significant T4 formation could be detected, confirming that 135 
Site A indeed has two donor tyrosines: Y234 and Y149. We also mutated four exposed 136 
tyrosines (4eY), suggested as being important for hormonogenesis21,24 and obtained the 137 
same activity as for un-mutated rTG. Therefore, at least under the conditions used, we 138 
unequivocally determined and validated the complete set of tyrosines involved in the 139 
four TG hormonogenic Sites A, B, C and D. The uniqueness of these tyrosine pairs is 140 
corroborated by the analysis of all tyrosine pairs at less than 15 Å distance from each 141 
other, calculated from the TG structure (Extended Data Figure 7 a & c). We found that 142 
only the tyrosines at TG's hormonogenic sites appear sufficiently close and exposed to 143 
permit T4 synthesis. Within the overall TG structure, Site A is located in the NTD, Site B 144 
in the CTD, Site C is at the C-terminus across the C2 dimer interface and Site D bridges 145 
the NTD and Flap (M domain) of the other subunit in the dimer (Figure 2b). 146 
Furthermore, we showed that all acceptor mutants with one hormonogenic site active at 147 
a time (Figure 3a) contribute to hormone formation and the sum of the concentrations 148 
measured individually recapitulates the total T4 amount produced by unmodified rTG. 149 
We conclude that TG synthesises seven molecules of T4 per dimer, since each TG dimer 150 
contains two sites (one per monomer) of A, B and D and only one Site C.  151 
Resolved Sites A, B and D do not show obvious structural similarity and active tyrosines 152 
are in solvent accessible and flexible regions (Figure 2a, Extended Data Figure 7a,c). A 153 
conserved lysine is found in proximity of the donor, and a conserved acidic residue (Glu 154 
or Asp) always precedes the acceptor 21. By mutagenesis of Site D, we showed that 155 
K1415 is not relevant, but D1309 is essential for hormonogenesis (Extended Data 156 
Figure 6d). Inserting an additional Ser-Asp sequence before acceptor Y1310 did not 157 
change the amount of T4 produced. Therefore, the presence of the aspartate seems to be 158 
overall more important than its distance to the donor tyrosine.  159 
Because in Sites A, B and D the donor backbone conformation is constrained within 160 
secondary structure elements, whereas the acceptor is in more flexible regions, the 161 
acidic Asp or Glu residues (pointing towards the solvent) could play a role in orienting 162 
the following acceptor towards the more rigid donor. There is no preceding acidic 163 
residue in the C-terminal Site C, where both acceptor and donor (Y2766 from the two 164 
chains of the dimer) are in unstructured regions with higher intrinsic flexibility. 165 
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Although the reaction mechanism of T4 synthesis from polypeptide chains remains to 166 
be established in more detail, four features seem to be crucial for hormonogenesis: 167 
tyrosine pairs must be solvent exposed to be iodinated, in proximity and in roughly 168 
antiparallel orientation, and in highly mobile regions of the protein in order to allow the 169 
significant bond rearrangement resulting in T4 synthesis.  170 
To validate our list of requirements for hormonogenesis from polypeptide chains, we 171 
set out to engineer synthetic T4 hormonogenic sites into the unrelated bacterial maltose 172 
binding protein (MBP). E. coli MBP naturally contains 15 tyrosines, mostly found in its 173 
hydrophobic core except the Y171-Y176 pair, which is in a solvent-exposed β-hairpin, 174 
and Y341, located in a solvent-exposed helix, facing the C-terminal helix (Extended Data 175 
Figure 7b & d). We engineered a putative partner tyrosine for Y341 first via the 176 
mutation R367Y (in a neighbouring helix) and second by inserting a tyrosine-containing 177 
peptide at the C-terminus: SDYS (C-ins1) or SGSDYS insert (C-ins2). We measured T4 178 
hormonogenesis with the same ELISA used for TG (Extended Data Figure 7a), at a 179 
concentration corresponding to a single TG site, and 10 times higher, to allow detection 180 
of marginal activities (Figure 3b). Unmodified MBP's T4 hormone production was only 181 
measurable at the higher concentration. We attribute this basal activity to the 182 
Y171/Y176 pair since it could be suppressed by introducing a Y171A mutation. The low 183 
level of T4 production can be attributed to a lack of flexibility of the backbone near 184 
Y171 and Y176, and to their relative orientations, which is different to any of the sites in 185 
TG. Equally, the hormonogenic activity was unchanged when introducing the pair 186 
Y341/Y367, presumably because both tyrosines were constrained by their rigid α-187 
helical backbone, and the coupling reaction could not occur with any effectiveness. The 188 
C-ins1 variant, producing a putative tyrosine pair with Y341, also showed low activity, 189 
possibly because the added linker was designed to be too short for the two tyrosines to 190 
come into proximity. However, and significantly, the amount of T4 measured for the 191 
two-residue longer C-ins2 MBP variant was comparable to a single site in TG (Figure 3b, 192 
Supplementary Video 2). Finally, with our ELISA we could also obtain modest T4 193 
synthesis from random tyrosine copolymers, as previously reported4 (Extended Data 194 
Figure 6e). 195 
Nature has selected the complex and large scaffold of the TG dimer to synthesise only 196 
seven molecules of hormones, using a chemical reaction involving radicals that could be 197 
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carried out by unfolded peptides or other less complex proteins. However, in the 198 
context of the thyroid gland and the iodine cycle in vertebrates, TG's structure 199 
effectively combines hormonogenesis with iodination of many other solvent exposed 200 
tyrosine residues for iodine storage21,13. The solvent exposure of tyrosines is 201 
presumably compensated by the exceptional solubility and stability that allows TG to 202 
persist at high concentrations in the harsh environment of the colloid. Moreover, the 203 
complexity of the TG molecule might fulfil further important roles in endocytosis, 204 
regulation of the T3/T4 ratio, TG proteolytic processing and in the trafficking to 205 
lysosomes25,26. The atomic structure of human TG presented here will enable further 206 
studies towards a deeper understanding of thyroglobulin within the thyroid, and its 207 
involvement in thyroid diseases27,28,29.  208 
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MAIN FIGURE LEGENDS 209 
Figure 1. The structure of human TG by cryo-EM 210 
a) Domain assignment of human thyroglobulin. Five regions (NTD, Core, Flap, Arm and 211 
CTD) contain domains of type-1 to type-3 TG repeats, as well as the choline esterase-like 212 
domain (ChEL), labelled as A to V. b) Structural gallery of all resolved TG domains. c) TG 213 
cryo-EM map where individual subunits are coloured blue and grey. The NTD crosses 214 
the major C2 interface. d) Ribbon diagram of panel c), coloured as in panel a). e) 215 
Schematic representation of TG structure in the same colour scheme as in a) and d). 216 
Figure 2. Identification and validation of hormonogenic donor-acceptor tyrosine 217 
pairs in TG  218 
a) Close-up view of the T4 hormonogenic sites resolved in the cryo-EM map, donor and 219 
acceptor tyrosines are highlighted in yellow. Site A suggests two donors, Y234 and 220 
Y149. b) Location of the four hormonogenic Sites A to D in the TG structure. c) T4 ELISA 221 
after in vitro iodination in triplicate. Bar plot and error bars indicate average and 222 
standard deviation. Replacing all acceptor tyrosines (Y) with phenylalanines (F) 223 
prevents hormone formation (4 Acc: 24, 2573, 2766, 1310). Replacing all five donors 224 
suppresses T4 synthesis (4 Donors (1): 2540, 2766, 108, 234; 4 Donors (2): 2540, 2766, 225 
108, 149; 5 Donors: 2540, 2766, 108, 234, 149). Replacing other tyrosines at the surface 226 
(258, 704, 1467, 1782) has no effect (4eY). 227 
 228 
Figure 3. Engineering T4 hormone synthesis by bacterial maltose binding protein 229 
(MBP) 230 
a) rTG mutants with only one site active at a time. T4 release measured with the same 231 
T4 ELISA as in Figure 2c. The sum of T4 produced by the individual sites recapitulates 232 
the T4 produced by WT. b) T4 ELISA after in vitro iodination of engineered MBP to 233 
reconstruct TG's hormonogenic sites. See text and Supplementary Video 2 for details. An 234 
MBP version adding a flexible SGSDYS tail to the C-terminus shows activity comparable 235 
to a single site on TG as shown in panel a). All measurements done in triplicate. Bar plot 236 
and error bars indicate average and standard deviation.   237 
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METHODS 238 
DNA constructs 239 
A gene encoding for full length human TG (Uniprot P01266) additionally containing a 240 
10x histidine tag at the C-terminus preceded by a TEV cleavage site was codon-241 
optimised for mammalian expression and purchased from GenScript (Piscataway, NJ). 242 
The gene was cloned with EcoRI and XhoI restriction sites (enzymes purchased from 243 
NEB) into vector pLEXm14 for recombinant expression in mammalian cells. Mutations 244 
were introduced by PCR and the purified overlapping fragments were assembled with 245 
the EcoRI/XhoI linearised vector by Gibson assembly (NEB).  246 
Maltose binding protein (MBP) constructs were purchased as gBlocks (IDT) and cloned 247 
using BlpI and NdeI restriction sites (enzymes purchased from NEB) into the pHis17 248 
bacterial vector, for the expression of N-terminally 6x histine-tagged MBP variants. A 249 
synthetic gene comprising human TPO (UniProt ID P07202) 1-838 with native 250 
extracellular signal sequence was cloned into pFastBac1 plasmid adding a C-terminal 6x 251 
histidine tag. All translated sequences of recombinant proteins used in this work are 252 
listed in SUPPLEMENTARY INFORMATION 1. 253 
Proteins, protein expression and purification 254 
Endogenous TG (eTG) from human thyroid glands was purchased from Biorad 255 
(Hercules, CA). We found it contains some T4, as measured by using our T4-ELISA, but 256 
not T3 (Extended Data Figure 6). It is also partially degraded, as shown by SDS-PAGE 257 
(Extended Data Figure 2a). While the protein behaved well when performing negative 258 
staining EM, it was challenging to produce specimens amenable to high resolution cryo-259 
EM. Therefore, eTG was deglycosylated with the addition of 1 µl/200 µg eTG of PNGaseF 260 
from NEB (Ipswich, MA) for 1 h at 37 ˚C and purified by size exclusion chromatography 261 
using a Superose 6 Increase 3.2/300 column (GE Healthcare), equilibrated with buffer 262 
T200 (50 mM Tris/HCl, 200 mM NaCl, pH 8.0).  263 
For the recombinant production of human TG (rTG), HEK293T (ATCC no. CRL-1573) 264 
cells were cultured as adherent monolayers until 90% confluency in Dulbecco’s 265 
modified Eagle’s medium (Sigma-Aldrich Company Ltd., Gillingham, UK) supplemented 266 
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with 10% foetal calf serum (v/v; Sigma-Aldrich Company Ltd.), L-glutamine and 267 
nonessential amino acids (Invitrogen Ltd., Paisley, UK), and transiently transfected with 268 
2 mg of DNA and 4 mg of polyethyleneimine (PEI; Sigma-Aldrich Company Ltd.) per litre 269 
of culture. We note that the involvement of glycans in TG dimer formation as revealed 270 
by the structure might explain the poor expression yields of thyroglobulin when 271 
produced in expression systems with reduced/altered glycosylation, such as insect cells, 272 
HEK293S GnT1-/- cells or HEK293T cells in the presence of kifunensine (data not 273 
shown). 274 
Five days later, the supernatant containing approximately 0.5 mg/L of secreted TG was 275 
harvested and filtered (0.22 µm) for protein purification. For smaller cultures (~125 276 
mL) the supernatant was diluted with an equal volume of buffer T200 containing 20 277 
mM imidazole. For volumes larger than 250 mL the supernatant was concentrated and 278 
buffer exchanged into buffer T200 using an Äkta Flux system (GE Healthcare). 279 
Subsequently, Ni-NTA agarose beads (QIAGEN, West Sussex, UK) were added to the 280 
supernatant (2 mL per litre of supernatant). The mixture was gently stirred at 4 ˚C for 1 281 
h and the beads collected by centrifugation at 600 xg for 5 min in 50 mL tubes (Falcon, 282 
BD Biosciences, Oxford, UK). The beads were poured into a 10 mL EconoColumn (Bio-283 
Rad Laboratories Ltd., Hemel Hempstead, UK) and washed with 10 column volumes 284 
(CV) of buffer T200, supplemented with increasing concentrations of imidazole (20 mM, 285 
50 mM, 80 mM), prior to elution with 5 column volumes of buffer T200 supplemented 286 
with 500 mM imidazole (all buffers adjusted to pH 8.0). Eluting fractions containing TG, 287 
according to SDS-PAGE analysis, were pooled and concentrated prior to further 288 
purification by size exclusion chromatography (SEC) using a Superose 6 Increase 289 
3.2/300 column (GE Healthcare), or a Superose 6 10/300 GL column for larger amounts 290 
of protein. Fractions containing TG were joined, concentrated by ultrafiltration, 291 
aliquoted at a concentration of ~0.5 mg/mL, flash frozen in liquid nitrogen and stored at 292 
-80 ˚C.  293 
For maltose binding protein (MBP) variants, the plasmid was transformed into 294 
chemically competent C41(DE3) E. coli cells. 100 mL bacterial cultures were grown in 295 
2xTY medium at 37 ˚C in the presence of 100 µg/mL ampicillin, and protein expression 296 
was induced at an optical density OD600 of ~1.0 with 1 mM IPTG for 5 hrs. Cells were 297 
harvested by centrifugation at 5000 xg, re-suspended in buffer T200, supplemented 298 
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with 20 mM imidazole, DNAse, RNaseA, lysozyme (Sigma Aldrich) and protease 299 
inhibitors (Roche), and lysed by sonication. The soluble fraction was separated by 300 
ultracentrifugation at 40,000 xg and MBP protein variants were purified as described 301 
for TG, with a SEC final purification step using a Superdex 200 3.2/300 column.  302 
For human TPO ectodomain expression in insect cells, bacmids were prepared using 303 
DH10EMBacY competent cells (Geneva Biotech) following the Bac-to-Bac Baculovirus 304 
Expression System user guide by Invitrogen. Sf9 cells were transfected with FuGENE 305 
Transfection reagent (Promega). V1 virus was used for large-scale protein production in 306 
400 mL, and cells were supplemented with 5-aminolevulinic acid, which is a precursor 307 
of the heme prostetic group and has been reported to increase specific activity of TPO30. 308 
Four days after infection, cells were harvested via centrifugation (800 xg, and then 309 
10.000, both at 4 °C) and the supernatant was concentrated by tangential flow filtration. 310 
The concentrated supernatant was dialysed against PBS, pH 7.4 and TPO was purified 311 
by nickel affinity purification (GE Healthcare HisTrap HP, 1 mL column) using as 312 
binding buffer PBS plus 20 mM imidazole, pH 7.4 and as elution buffer PBS plus 400 mM 313 
imidazole, also at pH 7.4. Relevant fractions were pooled, concentrated by ultrafiltration 314 
and TPO was further purified using a Superdex 200 10/300 column (GE Healthcare), 315 
pre-equilibrated with PBS, pH 7.4. TPO was concentrated to 1 mg/mL and flash frozen 316 
in liquid nitrogen for storage at -80 ˚C. The heme occupancy of TPO was estimated by 317 
measuring the ratio of absorbance at 412 nm and 280 nm which was 0.2, which roughly 318 
equates to 20% occupancy30.  319 
EM sample preparation and data collection 320 
Graphene oxide (GO) grids were prepared following a published procedure31 using as 321 
support Quantifoil Cu/Rh 200 mesh R2/2 grids. 3 µL of TG sample was applied to the 322 
GO grids at a concentration of approximately 0.05 mg/mL and plunge-frozen in liquid 323 
ethane using a Vitrobot Mark IV (Thermo Fisher). While eTG behaved better when 324 
deglycosylated, there was no difference between glycosylated and deglycosylated rTG. 325 
Therefore, we collected datasets of deglycosylated eTG and non-deglycosylated rTG.  326 
Images were acquired on a K2 Summit detector (Gatan) in counting mode using a Titan 327 
Krios G2 (Thermo Fisher) electron microscope at 300 kV. A Quantum GIF energy filter 328 
(Gatan) was used with a slit width of 20 eV to remove inelastically scattered electrons. 329 
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The eTG dataset was collected at eBIC (Diamond Light Source, UK) while the rTG 330 
dataset was collected at MRC-LMB. For the eTG dataset, 40 movie frames were 331 
recorded, using a fluency of 1.18 electrons per Å2 per frame, for a total accumulated 332 
dose of 47.2 electrons per Å2 at a pixel size of 1.043 Å on the specimen. For the rTG 333 
dataset 52 movie frames were recorded, using a fluency of 0.91 electrons per Å2 per 334 
frame, for a total accumulated dose of 36.3 electrons per Å2 at a pixel size of 1.149 Å on 335 
the specimen. Further details are presented in Extended Data Table 1. 336 
Cryo-EM image processing 337 
Movie frames were corrected for gain using a reference, motion-corrected and dose-338 
weighted using MOTIONCOR232. Aligned micrographs were used to estimate the 339 
contrast transfer function (CTF) in Gctf33. All subsequent image-processing steps were 340 
performed using single particle reconstruction methods in RELION 2.1 or 3.034,35. Poor-341 
quality images were discarded after manual inspection. Particles were initially manually 342 
picked in order to generate 2D class references for automated picking in RELION. After 343 
picking the whole dataset automatically, particles were extracted with 4 x 4 binning and 344 
two rounds of reference-free 2D classifications were performed. The particles belonging 345 
to the best 2D classes were extracted un-binned (400 pixels box size) and used for 3D 346 
reconstruction, applying C2 symmetry. The resolution was estimated with the FSC 347 
criterion of 0.143 and B-factor sharpening was applied, both using the 348 
relion_postprocess routine. Local map resolution was estimated with RELION. Bayesian 349 
polishing and per particle CTF and tilt correction were performed but did not provide a 350 
significant improvement in resolution.  351 
The central regions of the maps, corresponding to the C-terminal ChEL domains, were 352 
well defined (~3 Å in resolution), whereas peripheral regions corresponding to the 353 
Arms were noisy and at lower resolutions (~ 6 Å). In order to improve resolution 354 
especially in the Arm regions we expanded the dataset using the 355 
relion_symmetry_expand routine by the C2 symmetry and re-extracted the particles 356 
centred at the least resolved part of the map (Extended Data Figure 2d),36. After 357 
applying a soft mask to one half of the TG dimer, several cycles of refinement and 3D 358 
classification were run using solvent flattening. Although the overall resolution of the 359 
expanded and re-centred map was very similar to the C2 counterpart, the local 360 
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resolution and continuity of the density in the Arm region was significantly improved 361 
(Extended Data Figure 2e). The same procedure was applied to both eTG and rTG 362 
datasets, which at the end looked virtually identical as shown in Extended Data Figure 363 
2g. The best final maps we used for model building were the C2 map from the eTG 364 
dataset (overall 3.39 Å resolution) and the expanded map from the rTG dataset (overall 365 
3.67 Å resolution). In order to allow simultaneous model building in both maps the 366 
expanded rTG map was aligned and resampled onto the C2 map, and subsequently C2 367 
symmetrised for the final dimer TG model. 368 
Model building 369 
Following the domain annotations reported in UniprotKB for TG (P01266), we 370 
generated homology models with SWISSMODEL37, as reported in Extended Data Table 371 
2. We visually inspected the map and localised matching domains for some of the 372 
models, which we fitted by correlation in Chimera38. Firstly, the large ChEL domain at 373 
the dimeric TG interface was identified; secondly, triplets of TG type-1 repeats where 374 
fitted16,17. Their correct order was determined by the differences in side chain densities 375 
surrounding the CWC motif and the characteristic loop insertions of each domain. The 376 
best resolved type-3 repeat was domain U, which we built de novo in MAIN39 and used 377 
as a template to generate homology models for the other type-3 repeats Q, R, S and T. 378 
The connecting regions with unknown folds were build de novo in MAIN39 and COOT40, 379 
with help of secondary structure predictions (HHpred41, Jpred42). The correct 380 
assignment of the polypeptide chain register was often helped by the presence of large 381 
aromatic side chains and disulfide bond pairs, as well as the presence of glycosylation 382 
sites at Asn residues (17, plus 4 new sites which we identified, Extended Data Table 3, 383 
Extended Data Figure 5a-f). Residues 24 (acceptor Site A) to 29 were built tentatively 384 
into a map filtered to lower resolution using MAIN score map density modification 385 
procedure39, however their coordinates are only indicative and hence are included in 386 
the model as poly-alanine (Extended Data Figure 6g). 387 
Initially, the full model was built in one half of the rTG map (expanded, re-centred and 388 
masked) and refined using Phenix.real_space_refinement43. Subsequently, the full 389 
dimeric structure was generated by applying C2 symmetry and further refined in the 390 
C2-symmetrised rTG map. Final statistics and validation of the model are reported in 391 
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Extended Data Table 1 and Extended Data Figure 2. The resolution of the map is non-392 
uniform and consequently the model has variable quality depending on the map region. 393 
To illustrate this, per residue B-factor and per-residue map-to-model cross correlation 394 
plots as calculated in Phenix are provided in Extended Data Figure 3.  395 
Crosslinking and mass spectrometry analysis 396 
An rTG aliquot 100 µL at 0.5 mg/mL was buffer-exchanged using a Superose 6 Increase 397 
3.2/300 column (GE Healthcare), pre-equilibrated with 20 mM Hepes, 200 mM NaCl at 398 
pH 7.5. Pooled fractions were incubated for 2 h on ice at 0.5 mg/mL with or without 1 399 
mM BS3 (bis(sulfosuccinimidyl)suberate, Thermo Fisher). The crosslinking reaction was 400 
quenched by adding 50 mM ammonium bicarbonate and the product was analysed 401 
using a Superose 6 Increase 3.2/300 column pre-equilibrated in buffer T200 (Extended 402 
Data Figure 4). Gel bands corresponding to crosslinked rTG were excised and digested 403 
with trypsin (Pierce, Germany) following an in-gel digestion protocol44. The resulting 404 
tryptic peptides were extracted and desalted using C18 StageTips45. 405 
Enrichment of crosslinked peptides was accomplished by size-exclusion 406 
chromatography using a Superdex Peptide 3.2/300 column (GE Healthcare). Mobile 407 
phase consisted of 30% (v/v) acetonitrile and 0.1% trifluoroacetic acid, running at a 408 
flow rate of 10 µL/min. The earliest five peptide-containing fractions (50 µL each) were 409 
collected and dried in a vacuum concentrator. 410 
LC-MS/MS analysis was performed using an Orbitrap Fusion Lumos Tribrid mass 411 
spectrometer (Thermo Fisher Scientific, Germany), connected to an Ultimate 3000 412 
RSLCnano system (Dionex, Thermo Fisher Scientific, Germany). Samples were 413 
resuspended in 1.6% v/v acetonitrile 0.1% v/v formic acid and injected onto an EASY-414 
Spray column of 50 cm length (Thermo Fisher) running at 300 nL/min with mobile 415 
phases A (0.1% formic acid) and B (80% acetonitrile, 0.1% formic acid). Samples were 416 
eluted by applying a gradient ranging from 2% to 45% B over 90 min. Each gradient 417 
was optimised for the corresponding SEC fraction. After this, a washing step was 418 
applied in which the content of B was ramped to 55% and 95% within 2.5 min each, 419 
followed by 5 min at 95% B. Each fraction was analysed in duplicates. The settings of 420 
the mass spectrometer were as follows: data-dependent mode with 3s-top-speed 421 
setting; MS1 scan in Orbitrap at 120,000 resolution over 400 to 1,600 m/z; MS2-scan 422 
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trigger only on precursors with z = 3-6+; fragmentation by HCD employing a decision 423 
tree logic with optimised collision energies; MS2 scan in Orbitrap at resolution of 424 
30,000; dynamic exclusion was enabled upon single observation for 60 seconds. 425 
Generation of fragment spectra peak lists from raw mass spectrometric data used 426 
msConvert (version 3.0.11729), operating under default settings. Precursor m/z were 427 
recalibrated and the crosslink search was performed using Xi46 using TGs Isoform 1 428 
sequence without N-terminal signal peptide sequence and extra residues from TEV-429 
cleavage. Decoy sequences were generated by reversing the protein sequence. For the 430 
search MS1 and MS2 accuracies were set to 3 and 10 ppm, respectively. Tryptic peptides 431 
(full trypsin specificity) with up to four missed cleavages were allowed. BS3’s reaction 432 
specificity was restricted to the side chains of lysine, serine, threonine, tyrosine, as well 433 
as the protein N-termini. Carbamidomethylation on cysteine was set as fixed; oxidation 434 
on methionine, hydrolysed/aminolysed BS3 from hydrolysis or ammonia quenching on 435 
a free cross-linker end were set as variable modifications. Identified crosslinked peptide 436 
candidates were filtered to an FDR of 2% on residue-pair-level using XiFDR47. A list of all 437 
experimental crosslinks is reported in Supplementary Table 1. Inter- and 438 
intramolecular theoretical crosslinking pairs were calculated from our TG atomic 439 
structure and overlapped with the experimental pairs with a Xi score > 12 and an 440 
estimated FDR = 0 (Extended Data Figure 4c).  441 
 442 
T4 and T3 ELISA  443 
We produced TH from recombinant (non-iodinated) proteins following the procedures 444 
reported previously for poorly iodinated eTG22, and quantified the T4 and T3 products 445 
via ELISA designed to work in blood serum (Abcam, ab108661: Human Thyroxine 446 
ELISA Kit; Abcam, ab108664: Human Triiodothyronine ELISA Kit (free + total T3). To 447 
perform the assays, protein at a concentration of 0.1 µM was added to 1 mM KI, 24 mM 448 
glucose, 2 µg/mL glucose oxidase and 3 µg/mL lactoperoxidase (LPO) or TPO (Extended 449 
Data Figure 6c). All commercial reagents were purchased from Sigma. The iodination 450 
reaction was allowed to proceed for 10 min at 37 ˚C and then Pronase protease mix 451 
(Roche) was added at ~2.5 µg/mL to digest all enzymes, and TG to release TH. This was 452 
followed by heat inactivation for 15 min at 95 ˚C, a step that does not affect the stability 453 
of free T4 or T348. The reaction product was diluted to measure TH production in 454 
dynamic range compatible with the ELISA kits. Subsequently, we added BSA at a 455 
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concentration of 60 mg/mL to the mixture as an essential blocking agent, and added the 456 
mixture to ELISA plates for detection, following the manufacturer’s instructions. In 457 
order to check whether any of the iodination components were interfering with the 458 
ELISA (which is optimised for TH detection in serum) we performed the assay without 459 
iodide but adding known amounts of T4 or T3 (Sigma Aldrich). This yielded calibration 460 
curves similar to the ones provided by the manufacturer, and also showed good 461 
dynamic range (Extended Data Figure 6).  Only T4 was produced in detectable amounts 462 
in our in vitro TH production assay. Considering that TG has 3-4 sites, 0.1 µM was 463 
determined to be the optimal starting concentration for the assay. Positive controls 464 
were performed with eTG (containing some hormones and partly iodinated) and 465 
negative controls with T3 (tri-iodo-thyronine, Sigma), lysozyme and with FtsZ from 466 
Staphylococcus aureus, which does not contain tyrosines. Using our calibration curve, 467 
we converted the absorbance into T4 concentration, performed each measurement 468 
three times independently and reported the average and standard deviation values 469 
(Extended Data Figure 6, Figures 2 & 3). Recombinant TPO was added at a five times 470 
higher concentration, compensating for its heme content of only ~20 %. Tyrosine 471 
copolymers were purchased from Sigma Aldrich (P4659, P0151, P4409, P1800) and 472 
dissolved in T200 buffer. 473 
  474 
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ENTENDED DATA FIGURE LEGENDS 475 
Extended Data Figure 1. The iodine cycle in the thyroid gland and the chemistry of 476 
thyroid hormone formation. a) Iodide is extracted from the blood vessels and into the 477 
thyroid cells via the Na/I symporter (NIS). TSH binds TSH receptor (TSHR) to induce 478 
the expression of TG. TG is secreted into the extracellular lumen of follicular cells 479 
(colloid). DUOX and TPO catalyse the iodination of TG, therefore T4 (or T3) hormones 480 
are formed on the TG polypeptide chain. After hormonogenesis, TG is reimported and 481 
proteolysed in lysosomes to release T4/T3 into the blood. DEHAL1 deiodinates iodo-482 
tyrosines to recycle iodide in thyroid cells. b) T4 (or T3) synthesis from thyroglobulin 483 
(TG) in the thyroid gland. 484 
 485 
Extended Data Figure 2. Cryo-EM reconstruction of endogenous and recombinant 486 
thyroglobulin (eTG, rTG). 487 
a) SDS-PAGE of endogenous eTG from goitrous thyroid extracts and recombinant rTG 488 
expressed in HEK293T cells. b) Cryo-EM micrograph of eTG with calculated reference-489 
free 2D class averages below. Scale bar 200 Å. c) Cryo-EM micrograph of recombinant 490 
rTG with 2D class averages, showing the two proteins to be structurally identical at this 491 
level of analysis. Scale bar 200 Å. d) Schematic illustrating the C2 symmetry-expansion 492 
and re-centring procedure, which was used to enhance TG map quality in peripheral 493 
regions. For a detailed procedure see the Methods section ‘Cryo-EM image processing’. 494 
e) Local resolution of the C2 and symmetry-expanded and re-centred eTG maps. f) 495 
Flexibility of N-terminal domain (NTD) resulting in varying map quality and occupancy 496 
of this region in a number of 3D class averages (calculated in RELION). g) Fourier shell 497 
correlation (FSC) between RELION 'gold standard' half-maps and between the final eTG 498 
and rTG maps, showing their strong similarity. 499 
 500 
Extended Data Figure 3: Local properties of the atomic TG model. a) Per-residue 501 
atomic B-factor and cross correlation with the rTG map, plotted per residue number. b) 502 
Local B-factor colour-coded onto the surface of the TG structure. c) FSC between the 503 
map and model calculated for rTG. FSC 0.5 is indicated.  504 
 505 
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Extended Data Figure 4: Validation of TG's three-dimensional architecture by MS 506 
crosslinking. a) Size-exclusion chromatograms of rTG before and after BS3 crosslinking 507 
and subsequent SDS-PAGE (Coomassie stained). b) Negative staining micrograph of 508 
crosslinked rTG, showing the absence of higher-order structures caused by unwanted 509 
inter-dimer crosslinks. c) Plot representing experimental crosslinks (circles) 510 
overlapping with predicted crosslinks, calculated from the structure determined here. 511 
d) - f) Detail of key TG interfaces confirmed by the crosslinking. 512 
 513 
Extended Data Figure 5: TG cryo-EM map details. a) All disulfide bonds in TG 514 
included in the model (yellow spheres). b) Glycans detected in the cryo-EM maps and 515 
included in the TG atomic model (green spheres). c) Close-up view of a typical alpha 516 
helix in the TG cryo-EM map (part of the Core region). d) Close-up of a beta sheet in TG 517 
(part of the ChEL domain). e) Close-up of the disulfide bond C900-C921 (Core region). f) 518 
Map details of N2013 and N-linked GlcNAc between two TG subunits. g) Close-up views 519 
showing conformational disorder within the hormonogenic sites, making precise side 520 
chain placements difficult, but the backbone positions are resolved (rTG map). 521 
 522 
Extended Data Figure 6: Quantitative TH ELISA assays. a) Schematic summarising in 523 
vitro TH synthesis and quantification via ELISA assays. b) T4 assay calibration curves 524 
with added T4 under manufacturer-recommended and modified (T4 synthesis as 525 
performed here) conditions. c) Validation of the T4 ELISA assay. eTG presumably 526 
contains already reacted tyrosine side chains. rTG produces T4. Addition of iodide is 527 
required for the reaction to occur. LPO is as active as TPO, taking the reduced 20% 528 
heme content in our TPO into account. Lysozyme (some tyrosines), SaFtsZ (no 529 
tyrosines) and T3 produce no T4 signal. d) Mutating residues in hormonogenic Site D in 530 
a version of TG that is only active in Site D shows that a conserved lysine residue is not 531 
important for the reaction. Adding an extra Ser-Asp before Y1310 has no effect, but the 532 
mutation D1309S abolished activity. e) Synthesis of T4 from tyrosine copolymers as 533 
measured by the T4 ELISA assay. Only a polymer where tyrosines are spaced apart and 534 
preceded by Lys-Asp produce some T4. Note that activity is lower than in a single site of 535 
TG (or MBP, compare with Figure 4). f) T3 assay calibration curves with added T3 under 536 
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recommended and modified (as for T4) conditions. g) No significant T3 production was 537 
detected from iodinated rTG or eTG from goiter.  538 
 539 
Extended Data Figure 7: Tyrosine pair proximity plots for TG and MBP. a & b) 540 
Proximity plots of tyrosine residues closer than 15 Å to each other, calculated from TG 541 
a) and MBP b) atomic models (TG: this study; MBP PDB ID: 1ANF). The coordinates of 542 
each point in the plot represent a tyrosine pair position (residue number). For the TG 543 
dimer, the distance between tyrosines from the same or the other subunit in the dimer 544 
are shown in grey or black, respectively. In TG there are no more than five pairs that are 545 
exposed and in < 15 Å proximity at the same time, predicting the absence of other 546 
significant hormonogenic sites. In MBP only one pair closer than 15 Å is sufficiently 547 
exposed to be a candidate for hormonogenesis. c) & d) Ribbon diagram of TG and MBP 548 
where tyrosine residues are represented as spheres and coloured by B-factor, which 549 
largely indicates solvent exposed residues. 550 
 551 
Extended Data Table 1: Thyroglobulin (TG) cryo-EM and model statistics 552 
Extended Data Table 2: TG domain annotation  553 
Extended Data Table 3: List of N-linked GlcNac in TG structure 554 
  555 
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